Sugi Predict

Sugi Predict / Compounds / SCHEMBL3103837

SCHEMBL3103837

SCHEMBL3103837

CCOC(=O)/C=C/c1cccc2c1OCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.54
▸ MGAM O43451 1/20 0.49
▸ AMY1A P0DUB6 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ SI P14410 1/20 0.49
▸ MGAM2 Q2M2H8 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ CNKSR1 Q969H4 2/20 0.48
▸ AKT1 P31749 1/20 0.48
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ ALOX5 P09917 1/20 0.44
▸ DRD2 P14416 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103840 1.00 MAOB (0.54) MAOBMGAMAMY1AGAASI
SCHEMBL10973706 0.82 MAOB (0.55) MAOBMGAMAMY1AGAASI
SCHEMBL7518420 0.81 CA12 (0.44) MAOBKDM4ECNKSR1AKT1CA12
SCHEMBL8477313 0.81 CA12 (0.44) MAOBKDM4ECNKSR1AKT1CA12
SCHEMBL5478840 0.80 MAOB (0.61) MAOBMGAMAMY1AGAASI
SCHEMBL5478845 0.80 MAOB (0.61) MAOBMGAMAMY1AGAASI
SCHEMBL3570478 0.79 MAOB (0.60) MAOBKDM4EDRD2DRD3ALDH1A1
SCHEMBL3570479 0.79 MAOB (0.60) MAOBKDM4EDRD2DRD3ALDH1A1
SCHEMBL162076 0.78 KDM4E (0.77) MAOBKDM4ECNKSR1CA1CA2
SCHEMBL162075 0.78 KDM4E (0.77) MAOBKDM4ECNKSR1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200385340-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LTD (AU) 2020-12-10 — — US disclosed
US-10683263-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2020-06-16 — — US disclosed
EP-2826770-B1 ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY BIOTRON LTD (AU) 2018-09-12 — — EP disclosed
US-20170362170-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LTD (AU) 2017-12-21 — — US disclosed
US-20160376231-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2016-12-29 — — US disclosed
EP-2659885-B1 Hepatitis C Antiviral Compositions and Methods BIOTRON LTD (AU) 2016-11-09 — — EP disclosed
US-9440926-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2016-09-13 — — US disclosed
EP-2194976-B1 Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine BIOTRON LTD (AU) 2015-12-09 — — EP disclosed
US-20150023921-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED (AU) 2015-01-22 — — US disclosed
EP-2826770-A1 Acylguanidine compounds with antiviral activity Biotron Limited (AU) 2015-01-21 — — EP disclosed
EP-1902017-B1 Antiviral acylguanidine compounds BIOTRON LTD (AU) 2014-03-26 — — EP disclosed
US-8669280-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2014-03-11 — — US disclosed
US-20140066487-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2014-03-06 — — US disclosed
EP-2659885-A1 Hepatitis C Antiviral Compositions and Methods Biotron Limited (AU) 2013-11-06 — — EP disclosed
US-20100254942-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED (AU) 2010-10-07 — — US disclosed
EP-2194976-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS Biotron Limited (AU) 2010-06-16 — — EP disclosed
US-20090099239-A1 Antiviral Compounds and Methods BIOTRON LIMITED (AU) 2009-04-16 — — US disclosed
WO-2009018609-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTROM LIMITED (AU) 2009-02-12 — — WO disclosed
EP-1902017-A1 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2008-03-26 — — EP disclosed
WO-2006135978-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2006-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066487-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885
US-20100254942-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885
US-20150023921-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885
US-10683263-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885
US-20170362170-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885
US-20090099239-A1 Antiviral Compounds and Methods MAVS, ZC3HAV1, EIF2AK2 MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885
US-20160376231-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 MAOB 1895/4885MGAM 3128/4885AMY1A 4441/4885
US-20200385340-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 MAOB 883/4885MGAM 1742/4885AMY1A 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.